Your browser doesn't support javascript.
loading
Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice.
Smith, Katelyn V; Dunning, Jacqueline R; Fischer, Christina M; MacLean, Taylor E; Bosque-Hamilton, Joshua W; Fera, Liliana E; Grant, Jamaal Y; Zelle, David J; Matta, Lina; Gaziano, Thomas A; MacRae, Calum A; Scirica, Benjamin M; Desai, Akshay S.
Afiliação
  • Smith KV; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
  • Dunning JR; Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Fischer CM; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
  • MacLean TE; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
  • Bosque-Hamilton JW; Philips HealthTech, Cambridge, MA, USA.
  • Fera LE; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
  • Grant JY; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
  • Zelle DJ; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
  • Matta L; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
  • Gaziano TA; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
  • MacRae CA; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
  • Scirica BM; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
  • Desai AS; Cardiovascular Innovation Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
J Pharm Pract ; 35(5): 747-751, 2022 Oct.
Article em En | MEDLINE | ID: mdl-33813934
ABSTRACT

BACKGROUND:

Although strategies for optimization of pharmacologic therapy in patients with heart failure with reduced ejection fraction (HFrEF) are scripted by guidelines, data from HF registries suggests that guideline-directed medical therapies (GDMT) are underutilized among eligible patients. Whether this discrepancy reflects medication intolerance, contraindications, or a quality of care issue remains unclear.

OBJECTIVE:

The objective of this initiative was to identify reasons for underutilization and under-dosing of HFrEF therapy in patients at a large, academic medical center.

METHODS:

Among 500 patients with HFrEF enrolled in a quality improvement project at a tertiary center, we evaluated usage and dosing of 4 categories of GDMT ACE inhibitors/Angiotensin Receptor Blockers (ACE-i/ARB), Angiotensin Receptor-Neprilysin Inhibitors (ARNi), beta blockers, and Mineralocorticoid Receptor Antagonists (MRA). Reasons for nonprescription and usage of suboptimal doses were abstracted from notes in the chart and from telephone review of previous medication trials with the patient.

RESULTS:

Of 500 patients identified, 472 subjects had complete data for analysis. Among eligible patients, ACE-i/ARB were prescribed in 81.4% (293 of 360) and beta blockers in 94.4% (442 of 468). Of these patients, 10.6% were prescribed target doses of ACE-i/ARB and 12.4% were prescribed target doses of beta blockers. Utilization of other categories of GDMT was lower, with 54% of eligible patients prescribed MRAs and 27% prescribed an ARNi. In most cases, the reasons for nonprescription or under-dosing of GDMT were not apparent on review of the health record or discussion with the patient.

CONCLUSION:

Clear rationale for nonprescription and under-dosing of GDMT often cannot be ascertained from detailed review and is only rarely related to documented medication intolerance or contraindications, suggesting an opportunity for quality improvement.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca Tipo de estudo: Evaluation_studies / Guideline / Qualitative_research Limite: Humans Idioma: En Revista: J Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca Tipo de estudo: Evaluation_studies / Guideline / Qualitative_research Limite: Humans Idioma: En Revista: J Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos